AbbVie
ABBV
$185.48
Share price
-2.82%
Change (1 day)
9.31%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
EPS for AbbVie (ABBV)
EPS in 2025 (TTM): $2.36
According to AbbVie's latest financial reports the company's current EPS (TTM) is $2.36. In 2024 the company made an earnings per share (EPS) of $2.41 a decrease over its 2023 EPS that were of $2.75.
EPS history for AbbVie from 2013 to 2025
Annual EPS
| Year | EPS | Change |
|---|---|---|
| 2025 (TTM) | $2.36 | -2.08% |
| 2024 | $2.41 | -12.39% |
| 2023 | $2.75 | -58.95% |
| 2022 | $6.69 | 2.49% |
| 2021 | $6.53 | 121.58% |
| 2020 | $2.95 | -44.7% |
| 2019 | $5.33 | 45.84% |
| 2018 | $3.66 | 9.72% |
| 2017 | $3.33 | -9.54% |
| 2016 | $3.68 | 16.28% |
| 2015 | $3.17 | 184.1% |
| 2014 | $1.11 | -57.15% |
| 2013 | $2.60 |
EPS for similar companies or competitors
| Company | EPS | EPS differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $1.39 | -41.04% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $2.68 | 13.68% | 🇺🇸 USA |
 Eli Lilly LLY | $12.36 | 424.11% | 🇺🇸 USA |
 Amgen AMGN | $11.05 | 368.71% | 🇺🇸 USA |
 Gilead Sciences GILD | $4.78 | 102.75% | 🇺🇸 USA |
 Biogen BIIB | $10.16 | 330.96% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $1.56 | -33.85% | 🇬🇧 UK |
 AstraZeneca AZN | $2.50 | 6.25% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $3.03 | 28.52% | 🇺🇸 USA |